Showing results (461-470 of 516) with videos related to
Sort By:
Pageof 52
Journal of Neuro-Oncology|May 24, 2019
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)Kurt A Jaeckle, S K Anderson, Erin L Twohy, et al.Journal of Neuro-Oncology|June 6, 2019
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)Kurt A Jaeckle, S K Anderson, Erin L Twohy, et al.Clinical Lymphoma, Myeloma & Leukemia|August 31, 2022
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical TrialsJesse G Dixon, Çağlar Çağlayan, Dai Chihara, et al.Journal of Vascular and Interventional Radiology : JVIR|August 28, 2014
Survey of current status and physician opinion regarding ancillary staffing for the IR suiteHristina N Natcheva, James E Silberzweig, Christine P Chao, et al.The Lancet. Digital Health|December 13, 2024
Addressing the challenges of integrating digital health technologies to measure patient-centred outcomes in clinical registriesCaroline Marra, Tim Chico, April Alexandrow, et al.Pharmacoepidemiology and Drug Safety|November 4, 2020
Incorporating patient generated health data into pharmacoepidemiological researchAlison Bourke, William G Dixon, Andrew Roddam, et al.Blood|October 6, 2021
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trialsCarla Casulo, Jesse G Dixon, Jennifer Le-Rademacher, et al.Neuro-Oncology|June 28, 2025
Final Report on NCCTG N0877 (Alliance): A Phase II Randomized, Placebo-Controlled Trial of Chemoradiotherapy with or without Dasatinib for GlioblastomaWilliam G Breen, J G Dixon, S K Anderson, et al.Annals of the Rheumatic Diseases|June 17, 2016
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registersLouise K Mercer, Johan Askling, Pauline Raaschou, et al.Cancer|July 11, 2019
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872Evanthia Galanis, S Keith Anderson, Erin L Twohy, et al.Pageof 52